Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus
Frontiers in Pharmacology · 16.03.2023 · 14
DOI: 10.3389/fphar.2023.975880 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 16.03.2023. Verfasst von Xinrui Tan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Program of Hunan Province of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
To assess the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) used as an adjunct to insulin therapy in adults with type 1 diabetes.
Methods
A search of electronic databases (Medline, Embase, and the Cochrane Central Register of Controlled Trials) from 1 January 1950 to 23 May 2021 was conducted to find randomized controlled trials. The primary outcome was the change in HbA1c. Eight efficacy and six safety secondary endpoints were evaluated via meta-analysis. Weighted mean difference (WMD) and odds ratio (OR), alongside 95% confidence interval (CI), were calculated using the random effects model.
Results
Among 1,379 candidate studies, 11 trials comprising 2,856 participants satisfied the inclusion criteria. Overall, GLP-1 RA adjunctive therapy reduced HbA1c by −0.21% (95% CI, −0.33 to −0.10), weight by −4.04 kg (−4.8 to −3.27), systolic pressure by −2.57 mmHg (−4.11 to −1.03), and diastolic blood pressure by −1.02 mmHg (−1.99 to −0.06). In addition, there was a decrease in prandial insulin dose (WMD, −4.23 IU; 95% CI, −5.26 to −3.20), basal insulin dose (−2.40 IU; −3.93 to −0.87), and total insulin dose (−5.73 IU; −10.61 to −0.86). Moreover, GLP-1 RAs did not increase the incidence of severe hypoglycemia, diabetic ketoacidosis, or severe adverse events. However, GLP-1 RAs increased the incidence of gastrointestinal adverse events (OR, 2.96; 95% CI, 2.33–3.77).
Conclusion
Our meta-analysis of randomized clinical trials suggests moderate beneficial effects of GLP-1 RAs on the metabolic profile in patients with type 1 diabetes, without an increased risk of serious adverse events. Clinical Trial Registration: https://www.crd.york.ac.uk/PROSPERO ; Identifier: CRD 42020199840.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, Hunan, China.
Förderung
- Key Research and Development Program of Hunan Province of China
Zitieren
APA
Tan, X., Pan, X., Wu, X., Zheng, S., Chen, Y., Liu, D., & Zhang, X. (2023). Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.975880
Vancouver
Tan X, Pan X, Wu X, Zheng S, Chen Y, Liu D, et al. Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.975880
BibTeX
@article{Tan2023,
author = {Tan, Xinrui and Pan, Xiongfeng and Wu, Xiaochuan and Zheng, Songjia and Chen, Yuyao and Liu, Donghai and Zhang, Xingxing},
title = {Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.975880}
}
EUVIMED